Abstract. In this study we have used complementary biochemical and immunological techniques to establish that the lymphoma GP85 membrane glycoprotein is a transmembrane protein with a cytoplasmic domain that binds directly to ankyrin, a molecule known to link the membrane to the cytoskeleton.
Immunocytochemical studies indicate that an ankyrin-like protein accumulates underneath the lymphoma GP85 cap structure, suggesting an association of the ankyrin-like protein and GP85. This relationship has been further confirmed by the following results of binding and reconstitution experiments: (a) purified GP85 binds directly to an ankyrin-Sepharose column; (b) purified GP85 inserts into phospholipid vesicles in both the normal (fight side out) and reversed (inside out) orientation (and with only the reversed configuration permits binding of ankyrin to GP85); and (c) cleavage of GP85 with trypsin yields a 40-kD peptide fragment that is part of the cytoplasmic domain and contains the ankyrin binding site(s). Based on these findings, we suggest that the lymphoma GP85 transmembrane glycoprotein contains a cytoplasmic domain that is directly involved in linking ankyrin to the cytoskeleton. This transmembrane linkage may play a pivotal role in receptor capping and cell activation in lymphocytes.
I
NTERACTIONS between cytoskeletal proteins and the cytoplasmic domains of transmembrane proteins are believed to play a key role in several cellular activities, including ligand-induced receptor patching and capping (11, 27, 35, 36) , attachment of the cell surface to adhesion substrate (21, 45) , cell activation and proliferation (21) , cell motility (21) , and cell-cell interaction (21) .
The associations between transmembrane proteins and the cytoskeleton have been studied in great detail with erythrocytes. For example, purified cytoskeletal proteins have been bound to inside-out erythrocyte membrane vesicles in order to demonstrate that specific linkage molecules are required for the association between the cytoplasmic domain of transmembrane proteins and the cytoskeletal molecules (6, 38) . These studies have found that glycophorin, the major erythrocyte membrane glycoprotein, is linked to the actin-binding protein, spectrin, via band 4.1 (1, 17) . Similarly, band 3, the anion transport channel, is linked to spectrin (7) via the linker protein, ankyrin (4, 40) . Furthermore, the linkage between glycophorin and band 4.1 appears to be regulated by polyphosphoinositides (2) , and the band 3 ankyrin-binding site has been identified as a 40-43-kD amino-terminal proteolytic fragment that contains the most heavily phosphorylated region of the band 3 cytoplasmic domain (40) .
Analogs to proteins of the erythrocyte membrane-cytoskeleton complex such as spectrin (10, 23) , ankyrin (5, 9) , protein 4.1 (3, 8, 15, 22) , glycophorin (12) , and band 3 (19) have been found in a number of nonerythroid cells (29) . In particular, a number of immunoreactive forms of the erythrocyte band 3-like molecule have been found in different cell types, including lymphocytes, platelets, leukocytes, adult liver cells, lung carcinoma cells, embryonic liver cells, and normal human fibroblasts (29) . Further biochemical studies indicate that these band 3-like molecules are present as 60-, 48-, and 38-kD polypeptides in lung cell membrane (29), as 69-and 60-kD polypeptides in neoplastic cell membrane (29), and as 85-95-kD polypeptides in white blood cell membrane (29).
Recently, Bourguignon and co-workers have identified several membrane-cytoskeleton protein complexes in T lymphocytes. These include: (a) a complex that contains the membrane glycoprotein, GP180, and fodrin (a spectrin-like molecule), which binds to actin (10, 44) ; (b) a complex that consists of Thy-1 antigen and a 4.l-like protein that binds to fodrin and actin (8) ; and (c) a complex that consists of the membrane glycoprotein, GP85, and an ankyrin-like protein that also binds to fodrin and actin. The association between lymphoma GP85 and the ankyrin-like molecule appears to be analogous to that occurring between band 3 and ankyrin in erythrocytes (9) .
In this study we have used complementary biochemical and immunological techniques to further examine the transmembrane interaction occurring between lymphoma GP85 and the ankyrin molecule in mouse T-lymphoma cells. We speculate that this interaction may play a pivotal role in the mechanism of receptor capping and activation of lymphocytes.
Materials and Methods

Cell Culture
The mouse T lymphoma BW 5147 cell line (an AKR/J lymphoma line) was provided by Dr. R. Hyman (The Salk Institute, San Diego, CA). The cells were grown at 37* in 5% CO2/95% air using DME supplemented with 10% heat-inactivated horse serum (Gibco, Grand Island, NY), 1% penicillin, and i% streptomycin.
Protein Phosphorylation
Two procedures were used to metabolically label cellular phosphoproteins. Ha32PO4 (carrier free; ICN K&K Laboratories Inc., Plainview, NY) was added to cells in culture at 25 laCi/ml for 1 h or at 2 laCi/ml for 18 h. Radioactively labeled cells were washed and used for membrane preparations.
Radioactive Labeling of Cellular Proteins
Surface proteins and isolated cellular proteins were labeled with Na~ZSI using the iodogen method of Fraker and Speck (20) .
Plasma Membrane Isolation
T lymphoma cells (nonradioactively labeled, surface 125I labeled, or metabolically 32PO4 labeled) were harvested by low speed centrifugation (500 g~), washed twice with a phosphate-buffered Earle's salt solution (pH 7.3), and washed once in 20 mM Hepes (pH 7.3), 2 mM EDTA, 1 mM mercaptoethanol (HEM). Cells wore then resuspended in HEM buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 lag/ml aprotinin, 10 lag/nil leupeptin, and 5 mM iodoacetamide and lysed using a Dounce homogenizer. The lysate was centrifuged at 750 g, for 5 min at 4~ to remove nuclei, cell debris, and unlysed cells. The supernatant was then recentrifuged at 43,000 g~ for 20 min to pellet crude membranes. The crude membranes were resuspended in a solution containing 10% wt/wt sucrose made in HEM buffer plus 1 mM PMSE 10 lag/ml aprotinin, 10 lag/ml leupeptin, and 5 mM iodoacetamide. This membrane suspension was layered over a discontinuous gradient of 20, 30, and 40% wt/wt sucrose made in the same buffer and then centrifuged at 100,000 8~* for 2 h. The purified plasma membrane fraction was collected from the 30-40% interface (28) and washed with Dulbecco's PBS. Enzyme marker assays (5'-nucleotidase and/or Na+/K+-ATPase activities) demonstrated that the plasma preparation was at least 20-fold purified and contained negligible amounts of other membranous organelle contaminants.
Isolation of Human Erythrocyte Ankyrin
Human erythrocyte ankyrin was isolated by the procedure of Bennett and Stenbuck (7).
SDS-PAGE and Autoradiographic Analysis
Unless otherwise indicated, one-dimensional SDS-PAGE was conducted using a linear polyacrylamide gradient (5-15 %) slab gel and a discontinuous buffer system described by Laemmli (31) . In the case of two-dimensional SDS-PAGE the following conditions were used. For the first dimension, isoelectric focusing gels containing 1% ampholytes, pH 3.5-10.0, and 4% ampholytes, pH 5-7 (LKB Instruments, Inc., Gaithersburg, MD), were used. Linear (5-15%) polyacrylamide gradient gels were used (37) for the second dimension. For autoradiographic analysis, all gels were vacuumdried, exposed to Kodak X-ray (X-Omat XAR-5) film, and quantitated by densitometric tracing.
Negative Staining Procedures
Negative staining was done by adding three successive drops of liposomes to 0.2% Formvar-coated grids (200 mesh) and drying this with filter paper. Three drops of 1% uranyl acetate in water (pH 4.5) were then applied to the samples for 30 s and removed with filter paper. The samples were then examined in a Phillips 300 electron microscope.
Triton X-IO0 Extraction of Lymphoma Membranes
Crude or purified plasma membranes (nonradioactively labeled, surface 125I labeled, or metabolically 32po4 labeled) were resuspended in a solution containing 50 mM Tris-HC1 (pH 7.4), 5 mM EDTA, 1 mM PMSF, 10 p.g/ml aprotinin, 10 lag/ml leupeptin, 5 mM iodoacetamide, and 1% Triton X-100. The sample was incubated at 4~ for 1 h with constant shaking and centrifuged at 43,000 g~ for 20 min. The 43,000 g~ pellet fraction (Triton X-100-insoluble material) was discarded and the suporoatant fraction (Triton X-100-soluble material) was collected for the following wheat germ agglutinin (WGA)-Sepharose column chromatography analysis.
WGA-Sepharose Column Chromatography
Lymphoma membranes (nonradioactively labeled, surface ~2sI labeled, or metabolically 3zpo4 labeled) solubilized in Triton X-100 were incubated with 2 M urea/l.5 M NaCI and mixed with WGA-sepharose beads overnight at 4~ with constant shaking. The beads were then packed into a column and washed with 20 column volumes of a solution containing 50 mM Tris-HCI (pH 7.4), 5 mM EDTA plus 2 M urea. After washing offunbound material, the WGA-binding proteins were eluted from the column with a solution containing 0.75 M N-acetyi-glucosamine (GIcNAc), 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 1% deoxycholate. These WGA-binding proteins were used for the following liposome incorporation and various immunoprecipitation experiments.
Purification of Lymphoma GP85
WGA-specific binding proteins (nonradioactively labeled or surface ~25I labeled) were isolated by WGA-Sepharose affinity chromatography as described above. These proteins were concentrated using a microconcentrator (centricon 30; Scientific Systems Division, Amicon Corp., Danvers, MA), and applied to a 5-15% gradient SDS-gel. After electrophoresis, the protein band corresponding to GP85 was excised, eluted from the gel, and further iodinated (in order to label the entire GP85 molecule with a high specific activity) by the iodogen method as described previously. This purified radioactively labeled GP85 was used in the ankyrin-binding assays and peptide mapping analysis as described below.
Peptide Mapping of u~I-Surface-labeled GP85
Peptide mapping of GP85 was done using the method described by Cleveland et al. (14) . 125I-surface-labeled GP85 was purified through WGA-affinity column chromatography and analyzed on one-dimensional SDS-PAGE using a 5-15% linear polyacrylamide gradient gel and the discontinuous buffer system described by Laemmli (31) . The protein bands corresponding to t25I-GP85 were excised and transferred into the sample wells of a second dimension 15% SDS-gel. Variable amounts of V-8 proteinase (e.g., 0, 1, or 5 lag) were added to the GP85-containing wells. Gel electrophoresis was carried out at 32 mA until the V-8 treated GP85 migrated in the middle of the stacking gel. Electrophoresis was stopped for 15 rain to allow proteolytic digestion to occur. Subsequently, peptide fragments of GP85 digested by V-8 were subjected to further electrophoresis at a constant current of 20 mA using the discontinuous buffer system described by Laemmli (31) . Autoradiographic analyses of these gels were carried out according to the procedures described above.
replaced with a solution containing 10% acetic acid and 10% isopropanol. The container was gently swirled at room temperature for 2 h, during which time the solution was changed at least three to four times. The gel was then allowed to swell back to its original size in H20. It was then dried and subjected to autoradiography as described above.
Phosphoamino Acid A nalysis
32po4-1abeled lymphoma membrane glycoprotein GP85 purified using WGA-Sepharose affinity chromatography was subjected to SDS-PAGE analysis. The protein band corresponding to GP85 was excised and eluted from the pelyacrylamide gel by electroelution using the method described by Hunkapiller et al. (25) , The eluted GP85 was hydrolyzed at I10~ for 2 h by the method described by Cooper et al. (16) , and the phosphoamino acids were separated on 3-ram chromatographic paper 0Vhatman Inc., Clifton, NJ) at pH 3.5 for 2 h at 2,000 V. The phosphoamino acid standards (i.e., phosphoserine, phosphotyronine, and phosphothreonine) were mixed with 32PO4-1abeled samples, coanalyzed, and identified by minhydrin staining. The 32PO4-1abeled phosphoamino acids were detected by autoradiography (X-Omat XAR-5 film) at -70~
lmmunoprecipitation Procedures
An aliquot of affinity-purified surface 12SI-labeled lymphoma GP85 was incubated with either rat antilymphocyte Pgp-1 monoclonal antibody (provided by Dr. Hyman), or rabbit antierythrocyte band 3 antiserum (provided by Dr. Bennett) for 1 h at 4~ As controls, either anti-Pgp-I or anti-band 3 antibody was ommitted, or preabsorbed serum (rat anti-Pgp-l-free serum or rabbit anti-band 3-free serum) was used. Subsequently, goat anti-rat IgG or goat anti-rabbit IgG at 100 Ixg/ml was added to the rat anti-Pgp-I (or anti-Pgp-l-free serum, control samples) or rabbit anti-band 3 (or anti-band 3-free serum, control samples)-reacted samples, respectively. These samples were incubated at 4~ overnight. The resulting immunoprecipitates were centrifuged at 700 g~ for 10 min to form pellets, and washed three times with a solution containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM EDTA, and 3 % deoxycholate using the same centrifugation conditions. The immunoprecipitates were solubilized in a solution of 20 mM Tris-HCI buffer (pH 7.4) containing 0.1 M 2-mercaptoethanol, 2% SDS, and 0.003 % bromophenol blue. These proteins were then analyzed by SDS-PAGE in a 5-15 % exponential gradient gel and by autoradiography.
Incorporation of Lymphoma GP85 into Phospholipid Vesicles (Liposomes)
L-lecithin (10 nag) and phosphatidyl serine (1 rag) (Avanti Polar Lipids, Inc., Birmingham, AL) were lyophilized and dissolved in 2 ml of a solution containing 3% cholate, 50 mM Tris-HCl (pH 7.4), and 5 mM EDTA. This lipid solution was then mixed with lymphoma glycoproteins (100 gg/rnl) (either ~25I-surface labeled, metabolically 32PO4 labeled, or unlabeled) isolated from the WGA-Sepharose column as described above for "~1 h at room temperature. The protein/lipid mixture was then dialyzed for 2 d in 2 liters of 50 mM Tris-HCI (pH 7.4), 5 mM EDTA. This dialysis buffer was changed twice to remove the free detergent. The liposomes were layered over a discontinuous step-gradient consisting of 60, 40, 25, and 10% wt/vol sucrose made in 50 mM Tris-HCl (pH 7.4), 5 mM EDTA and then centrifuged at 120,000 g~ for 18 h at 4~ Control liposomes in which no protein was incorporated were prepared in an identical manner. Some 32PO4-GP85-containing liposomes were incubated with trypsin conjugated to Sepharose beads (trypsin-Sepharose or immobilized trypsin) (100 gg/ml) at 22 ~ for 10 min to remove the 32PO,-labeled cytoplasmic domain of GP85, which was protruding from the outside surface of the liposomes. At the end of the trypsinization reaction, the trypsin beads were centrifuged at 1,000 g,~ for 5 min. The liposomes (with or without trypsin treatment) were selectively banded on the top of the 10% sucrose. The gradients were fractionated from top to bottom and assayed for radioactivity to determine the location of liposome-associated ~25I-or 32po4-1abeled glycoproteins. Radioactively labeled samples from the gradients were analyzed by SDS-PAGE and autoradiography as described above. Unlabeled proteins that were successfully incorporated into liposomes were used for ankyrin binding experiments.
ml-Ankyrin Binding to GP85 Containing Phospholipid Vesicles (Liposomes)
The unlabeled GP85-containing phospholipid vesicles (liposomes) were incubated with 125I-ankyrin for 2 h at 4~ These liposomes were then passed through a Sepharose 2B-300 column to separate t2~l-ankyrin-bound liposomes (preferentially eluted at the void volume) from free 125I-ankyrin. To determine nonspecific binding of ~2SI-ankyrin to the liposomes, either GP85-containing liposomes that were treated with trypsin or pbospholipid vesicles that contained no protein were used in this ~25I-ankyrin binding assay.
mI-GP85 Binding to Ankyrin-conjugated Sepharose Beads
Ankyrin was purified from 40-ml erythrocyte ghosts using the procedure of Bennett and Stenbuck (7). This protein was then concentrated and conjugated to Scpharose-beads overnight at 4*(2. Unbound sites were satorated with I M ethylamine (pH 9.0) overnight. The beads were then washed extensively with a solution of 0.5 M NaC1, 0.1 M acetate (pH 4.0) buffer and then with a solution of 0.5 M NaCl, 0.1 M Tris-HC1 (pH 8.0) buffer. After three washes they were washed with Dulbecco's modified PBS. An aliquot of beads (100 gl) was mixed with l~SI-laboled GP85 (1 x 106 cpm) and allowed to bind at 4~ overnight. In control experiments ~I-labeled lymphoma GP85 was incubated overnight with soluble ankyrin (100 gg/ml) and this mixture was then added to the ankyrin beads.
Identical ankyrin-binding experiments were performed using trypsintreated ~25Iqabeled lymphoma GP85. The preparation of trypsin-treated GP85 was as follows. 12~I-labeled GP85 (100 gg/ml) was incubated with trypsin that was conjugated to Sepharosr beads (100 gg/ml) (trypsin-Sepharose or immobilized trypsin) at 35~ for 10 rain with constant shaking. The trypsinization reaction was terminated by adding 100 mM PMSF (with a final PMSF concentration of 10 raM). Subsequently, trypsin-Sepharose beads were centrifuged at 10,000 g,v for 4 rain. The trypsin-digested GP85 polypeptide fragments were used to bind ankyrin-Sepharose beads as described above.
After binding, the beads were transferred in disposable l-ml plastic columns and washed extensively with Dulbecco's modified PBS. The degree of radioactive binding was determined by counting the beads with a gamma counter (model 5500; Beckman Instruments, Inc., Palo Alto, CA). The protein was then recovered by eluting it with 200 t~l of a solution containing 20 mM Tris-HCl (pH 6.8), 2 % SDS, 0.1 M 2-mereaptoethanol, and 0.003 % bromophenol blue. The eluted protein was examined by one-dimensional SDS-PAGE using a 5-15% linear gradient gel followed by autoradiography.
Results
Identification of Lymphoma GP85 as a Transmembrane Protein
Determination of the GP85 transmembrane characteristics was achieved by surface labeling techniques, internal 32PO4 labeling, and liposome binding studies. Our results showed that: (a) GP85 could be surface iodinated (Fig. 1, lane C) ; (b) GP85 bound to a WGA-Sepharose column and was specifically eluted with N-acetyl glucosamine (Fig. 1 , curves A and B) (both of these findings indicate that GP85 is a surface glycoprotein); and (c) GP85 could be phosphorylated by intracellular kinase(s) (Fig. 1, lane D) . Analysis of the phosphorylated GP85 suggested that this phosphorylation was sensitive to alkali treatment (Fig. 2 A, lane 1 vs. lane 2) that preferentially removed serine and threonine, but not tyrosine, residues. Phosphoamino acid analysis revealed that the phosphorylation of GP85 occurred primarily at serine and threonine residues (Fig. 2 B) . Therefore, the phosphorylated portion of GP85 (presumably at the cytoplasmic domain) may serve as an intracellular substrate primarily for serine-and threonine-specific, but not tyrosine-specific, kinases. Finally (d) GP85 labeled with ~25I and 32po4 could be successfully incorporated into phospholipid vesicles, as shown in Fig. 3 (curves A and B) . After sucrose density gradient centrifugation, the liposomes containing 125I-and 32PO4-1abeled protein banded on the top of the gradient (Fig.  3, curves A and B) . SDS-PAGE and autoradiographic analysis of the gradient indicated that the liposomes were spe- cifically enriched for GP85 (Fig. 3, lane C) . The fact that GP85 can be incorporated into phospholipid vesicles implies the existence of a hydrophobic domain in the molecule that is required for all transmembrane proteins.
Immunological Analysis of Lymphoma GP85
GP85 was found to cross-react with antibodies specifically raised against lymphocyte Pgp-1 glycoprotein (Fig. 4 A) . GP85's molecular mass, isoelectric point (PI), ~4.5 to 5.0 (Fig. 5) , and peptide mapping pattern (Fig. 6 A-C) were very similar to those of Pgp-1. In addition, GP85's cross-reactivity with the erythrocyte band 3 molecule suggests that this protein is an immunoreactive form of band 3-like molecule (Fig. 4 B) . No GP85-associated material was observed in control samples when either the primary antibody was eliminated or preabsorbed serum (anti-Pgp-l-free serum or antiband 3-free serum) was used (Fig. 4, C and D) .
Interaction of GP85 with Ankyrin Colocalization of Lymphoma GP85 Glycoprotein and An-
kyr/n. In a previous study, lymphoma GP85 has been shown to be closely associated with lymphocyte ankyrin-like molecules (9) . In order to verify this finding, we have used double immunofluorescent staining to simultaneously localize GP85 and intracellular membrane linkers, such as ankyrin, in lymphocytes. Our results showed that there was a preferential accumulation of intracellular ankyrin directly underneath GP85 caps (Fig. 7, A and B) indicating a close association between GP85 and ankyrin.
Demonstration of the Specific Binding between GP85
and uSI-Ankyrin. Binding between the erythrocyte band 3 protein and ankyrin has been extensively studied in reconstitution experiments that employ inside out erythrocyte vesicles and purified ankyrin (6, 38) . However, in the lymphocyte system it is difficult to obtain inside out membrane vesicles. Therefore, GP85 was reconstituted into synthetic phospholipid vesicles (liposomes) in order to examine the possibility of direct ankyrin binding to the cytoplasmic domain of GP85. The material used in this experiment is described in Fig. 3 , which shows that GP85 was the only surface protein incorporated in the phospholipid vesicles. GP85, metabolically labeled with 32po4, was used to establish the orientation of the GP85 incorporated into phospholipid vesicles (Fig. 8, A and C) . The fact that •50% of the a2PO4-labeled material (Fig. 8 A) could be released from the liposome by trypsin digestion (Fig. 8 B1-3) suggests that a large portion of the 32PO4-1abeled GP85's cytoplasmic domain is protruding from the outside surface of the phospholipid vesicle. Consequently, these protruding portions of the GP85's cytoplasmic domain (analogous to the inside out vesicle preparation in erythrocytes) should be available for an ankyrin binding. The GP85-containing phospholipid vesicles (showing available cytoplasmic domain) were then used to carry out ~25I-ankyrin-binding assays. Our results showed that there was a fivefold increase in t25I-ankyrin binding to the GP85-containing vesicles (Fig. 8 D) , as compared with the control liposomes that were either treated with trypsin or did not contain any GP85 (Fig. 8 E) . These experiments all indicate that GP85 binds directly to ankyrin.
Another approach used in this study involved labeling all Figure 3 . the GP85 molecules with ~25I and incubating these molecules with ankyrin-conjugated Sepharose beads. Our results showed that ~25I-labeled GP85 specifically bound to the ankyrin beads (Fig. 9 A) . As a control, the GP85 was preincubated with an excess amount of unlabeled ankyrin. Under this condition, the binding of GP85 to the ankyrin beads decreased significantly (Fig. 9 B) . When GP85 (Fig. 10 A) was partially digested by trypsin into several fragments (i.e., 40 and 22 kD; Fig. 10 B) , only the intact GP85 molecule and the 40-kD (but not 22-kD proteolytic fragments preferentially bound to ankyrin beads (Fig. 10 C) . When metabolically 32PO4-1abeled GP85 was extensively digested by trypsin, the 40-kD phosphorylated (but not 22-kD) peptide also specifically bound to the ankyrin beads (Fig. 10 D) . This assay showed that the association between the 40-kD peptide and the ankyrin beads was specific (Fig. 11 A) because free excess soluble ankyrin successfully competed with the peptide for ankyrin binding sites on the beads (Fig. 11 B) . Therefore, it is suggested that the 40-kD proteolytic fragment of GP85 contains the ankyrin binding site.
Discussion
In this study we have found that lymphoma GP85 is a transmembrane glycoprotein that displays the following characteristics: (a) it can be surface-labeled with Nat25I (Fig. 1) ; (b) it contains WGA-binding sites (Fig. 1) ; (c) its cytoplasmic Figure 11 . Binding of the peptide fragments of (trypsintreated) 125I-GP85 to ankyrinSepharose beads. The entire GP85 molecule was first labeled with '25I. The radioactively labeled GP85 was partially digested by Sepharose-conjugated trypsin (immobilized form), and then incubated with ankyrin-Sepharose beads. Peptide fragments of GP85 bound to the ankyrin-Sepharose beads before (A) and after (B) pretreatment with an excess amount of soluble ankyrin.
domain can be phosphorylated by intracellular kinase(s), primarily on serine and threonine residues (Fig. 2) ; and (d) it can be incorporated into phospholipid vesicles, implying the existence of a hydrophobic domain in the molecule (Fig. 3) .
Further studies show that lymphoma GP85 exhibits crossreactivity with antibody raised against T lymphocyte Pgp-1 (Fig. 4, lanes 1 and 3) . Pgp-1 is a 95-kD glycoprotein expressed predominantly on the surface of bone marrow prothymocytes, on T lymphoma cells and on a few thymus cells (32) (33) (34) 46) . The discrepancy between the molecular masses Figure 10 . Analysis of ankyrin-binding domain of GP85 using ankyrin-Sepharose beads and SDS-PAGE/autoradiography. The entire GP85 molecule was first labeled with '251. Intact GP85 and peptide fragments of GP85 (partially digested by immobilized trypsin) were bound to ankyrin-Sepharose beads as described in Materials and Methods. (Lane A) Autoradiogram of '25I-labeled intact GP85 bound to ankyrin-Sepharose beads. (Lane B) Autoradiogram of total trypsin-digested peptide fragments of '25I-labeled GP85 before binding to ankyrin-Sepharose beads (Note that the intact GP85 and two fragments of 40 and 22 kD were present.) (Lane C) Autoradiogram of peptide fragments of '25I-labeled GP85 bound to ankyrin-Sepharose beads. (Note that both intact GP85 and a fragment of 40 kD (but not 22 kD) were preferentially bound to the ankyrin-Sepharose beads.) (Lane D) Autoradiogram of peptide fragments of metabolically 32po4-1abeled GP85 bound to ankyrinSepharose beads. In this case, trypsin digestion of GP85 is more complete. (Note that, again, a fragment of 40 kD [but not 22 kD] was preferentially bound to the ankyrin-Sepharose beads.) determined for Pgp-1 (95 kD) and GP85 (85 kD) could result from the different SDS-PAGE systems used by Trowbridge's (33, 46) and our laboratories. The GP85 containing (Pgp-1 § thymocytes include progenitor ceils that are able to home back to the thymus of an irradiated animal and proliferate, thereby producing a transient thymus repopulation (33). We believe that GP85 (Pgp-1) plays an important role in the differentiation of T lymphocytes.
Recently, several authors have suggested that a family of cell surface receptors with a common sequence homology (called "integrins') are involved in cell adhesion (45) , cell migration (41), thrombosis (13) , and lymphocyte helper-and killer-related activities (26, 42) . Integrins include cell surface receptors for extracellular matrix proteins (26, 30) , the major glycoprotein complex on the platelet surface (GPI]bIIIa) (13, 26) , and several groups of proteins on lymphoid and myeloid cells (LFA-1, MAC-l, P150,95 and VLA antigens) (26) . Lymphocyte integrin, LFA-1, acts as a general adhesion protein that participates in cell-mediated killing and antigenspecific helper activity (26, 30) . LFA-1 is composed of an a-subunit with a molecular mass of ~180 kD and a I]-subunit with a molecular mass of 85-95 kD (30) . The fact that lymphoma 85 and 180 kD (gp 180) can be coisolated from WGA columns (Fig. 1) , and cosedimented on a sucrose gradient as a large complex (data not shown), suggests that lymphoma GP85 may be a subunit of lymphocyte integrin. In addition, transmembrane interactions appear to occur between integrins and the cytoskeleton (13, 26, 30) during various cellular events. However, at present, little is known about the linkage between the lymphocyte integrin molecule and the cytoskeleton.
Currently, the most extensively characterized plasma membrane-cytoskeleton organization is that of erythrocytes (1, 2, 6, 17, 38) . The predominant linkage between the erythrocyte cytoskeleton and membrane occurs at the anion channel, band 3 (40) . Band 3 protein binds via its cytoplasmic domain to the linker molecule, ankyrin. Ankyrin binds to the band 3 molecule through high affinity sites (24) and possibly through a lipid molecule, palmitate (39, 43) . Ankyrin also binds to the actin-binding protein, spectrin (10, 23) , completing the linkage between the membrane and the cytoskeleton.
The cytoplasmic domain of erythrocyte band 3 is a known substrate for endogenous and exogenous protein kinases, including tyrosine kinase (40) . Several investigators using a limited proteolysis of erythrocyte band 3 have demonstrated that the 40- kD proteolytic fragment of band 3 (cytoplasmic  domain) contains the ankyrin-binding site (4, 40) . Recently, Davis and Bennett reported that a proteolytic fragment of brain membrane-associated ankyrin-binding protein is similar in size (molecular mass, 40 kD) to the cytoplasmic domain of the erythrocyte band 3 (18) . These data suggest that the membrane-associated ankyrin-binding domain may be present in different cell types (18) . Another erythrocyte membrane-associated skeletal protein, band 4.1, has been shown to associate with band 3 via low affinity binding sites (40). It is not known whether lipids play any role in the linkage of band 3 and the 4.1 protein or whether band 3-4.1 protein complex is present in nonerythroid cells. At the time, many unanswered questions remain concerning the properties of these linkages, particularly with regard to the membrane-associated binding domain(s) for the cytoskeleton.
In this paper, we have presented evidence that GP85 of mouse T lymphoma cells is very similar, if not equivalent, to erythrocyte band 3 glycoprotein. Our results indicate that lymphoma GP85 has erythrocyte band 3-like properties because it is a transmembrane glycoprotein and cross-reacts with specific antibodies raised against erythrocyte band 3 molecules. In erythrocytes, inside out (reversed) vesicles are used extensively to elucidate transmembrane-cytoskeletal interactions. However, in nonerythrocytes, it is difficult to prepare inside out vesicles. Therefore, it is necessary to reconstitute the membrane glycoprotein in synthetic phospholipid vesicles (Fig. 3) and perform binding studies between GP85 and ankyrin (Fig. 8) . Our preliminary data using silver-stained SDS-PAGE and autoradiographic analyses indicate that GP85 is the major silver-stained (data not shown), surface-iodinated, and phosphorylated protein (Figs.  1-3 ). Using this method with studies employing ankyrinconjugated sepharose beads, we have also found that GP85 binds directly to ankyrin (Fig. 9) and that the cytoplasmic domain of GP85, a 40-kD proteolytic fragment (Figs. 10 and  11) contains the ankyrin binding site. This transmembrane linkage through GP85 and ankyrin to the cytoskeleton could play a pivotal role in a number of important physiological activities, such as receptor capping, cell activation, cell-cell interaction, and cell adhesion. More work is needed to determine the precise sequences involved in GP85 for ankyrin binding, and to investigate whether GP85 is an anionic transporter for lymphocytes and also an integrin subunit.
